HRP20210551T1 - Postupak kristalizacije derivata aripiprazola u formulacijama sa produženim oslobađanjem za liječenje shizofrenije - Google Patents

Postupak kristalizacije derivata aripiprazola u formulacijama sa produženim oslobađanjem za liječenje shizofrenije Download PDF

Info

Publication number
HRP20210551T1
HRP20210551T1 HRP20210551TT HRP20210551T HRP20210551T1 HR P20210551 T1 HRP20210551 T1 HR P20210551T1 HR P20210551T T HRP20210551T T HR P20210551TT HR P20210551 T HRP20210551 T HR P20210551T HR P20210551 T1 HRP20210551 T1 HR P20210551T1
Authority
HR
Croatia
Prior art keywords
mixture
crystallized particles
temperature
target temperature
compound
Prior art date
Application number
HRP20210551TT
Other languages
English (en)
Croatian (hr)
Inventor
Wilfredo Morales Jr.
Tarek A. Zeidan
Renato A. Chiarella
Steven G. Wright
Jason M. Perry
Original Assignee
Alkermes Pharma Ireland Limited
Wilfredo Morales Jr.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Pharma Ireland Limited, Wilfredo Morales Jr. filed Critical Alkermes Pharma Ireland Limited
Publication of HRP20210551T1 publication Critical patent/HRP20210551T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
HRP20210551TT 2014-08-25 2015-08-24 Postupak kristalizacije derivata aripiprazola u formulacijama sa produženim oslobađanjem za liječenje shizofrenije HRP20210551T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462041341P 2014-08-25 2014-08-25
PCT/US2015/046525 WO2016032950A1 (en) 2014-08-25 2015-08-24 Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia
EP15836431.5A EP3185867B1 (en) 2014-08-25 2015-08-24 Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia

Publications (1)

Publication Number Publication Date
HRP20210551T1 true HRP20210551T1 (hr) 2021-08-20

Family

ID=55347322

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20210551TT HRP20210551T1 (hr) 2014-08-25 2015-08-24 Postupak kristalizacije derivata aripiprazola u formulacijama sa produženim oslobađanjem za liječenje shizofrenije

Country Status (20)

Country Link
US (5) US10064859B2 (enExample)
EP (2) EP3185867B1 (enExample)
JP (2) JP6591546B2 (enExample)
CN (2) CN107106556B (enExample)
AU (2) AU2015306910B2 (enExample)
CA (1) CA2959329C (enExample)
CY (1) CY1124058T1 (enExample)
DK (1) DK3185867T3 (enExample)
ES (2) ES2862098T3 (enExample)
HR (1) HRP20210551T1 (enExample)
HU (1) HUE054641T2 (enExample)
IL (1) IL250661B (enExample)
LT (1) LT3185867T (enExample)
MA (2) MA40480B1 (enExample)
PL (1) PL3185867T3 (enExample)
PT (1) PT3185867T (enExample)
RS (1) RS61709B1 (enExample)
SI (1) SI3185867T1 (enExample)
SM (1) SMT202100212T1 (enExample)
WO (1) WO2016032950A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014080285A2 (en) 2012-09-19 2014-05-30 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
US10016415B2 (en) 2014-08-18 2018-07-10 Alkermes Pharma Ireland Limited Aripiprazole prodrug compositions
JP6591546B2 (ja) * 2014-08-25 2019-10-16 アルカームス ファーマ アイルランド リミテッド 統合失調症治療用の持続放出型製剤におけるアリピプラゾール誘導体の結晶化プロセス
EP3294724A4 (en) * 2015-05-08 2018-11-21 Davuluri, Ramamohan Rao Improved process for the preparation of aripiprazole with reduced particle size
WO2018104953A1 (en) * 2016-12-07 2018-06-14 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 7-{4-[4-(2,3-dichlorophenyl)-piperazin-1-yl]butoxy}-2oxo-3,4-dihydro-2h-quinolin-1-yl)methyl dodecanoate
EP3658540B1 (en) 2017-07-28 2021-12-01 Interquim, S.A. Process for the preparation of aripiprazole lauroxil
CN110218209B (zh) * 2018-03-02 2022-09-30 上海现代药物制剂工程研究中心有限公司 一种依匹哌唑月桂酸酯的晶型a、其制备方法及应用
WO2019173230A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN113105389B (zh) * 2021-04-16 2022-04-08 江苏海洋大学 一种阿立哌唑药物共晶及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US20050032811A1 (en) 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
KR100931784B1 (ko) * 2003-10-23 2009-12-14 오츠카 세이야쿠 가부시키가이샤 방출조절성 멸균 아리피프라졸 주사제, 그 제조방법
TWI371274B (en) * 2003-10-23 2012-09-01 Bristol Myers Squibb Co Process for making sterile aripiprazole of desired mean particle size
KR20100099292A (ko) 2007-12-19 2010-09-10 얀센 파마슈티카 엔.브이. 장기 작용성 주사가능 팔리페리돈 에스테르와 관련된 투여 요법
US20110003823A1 (en) 2008-08-01 2011-01-06 Alpha Synergy Development, Inc. Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage
AU2010266018B2 (en) * 2009-06-25 2014-01-09 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
WO2012077134A1 (en) * 2010-12-07 2012-06-14 Ind-Swift Laboratories Limted Process for preparing aripiprazole polymorphs
CA2824045C (en) * 2011-01-07 2019-04-09 Neodyne Biosciences, Inc. Wound or skin treatment devices and methods
MX358344B (es) 2011-03-18 2018-08-15 Alkermes Pharma Ireland Ltd Composiciones farmaceuticas que comprenden un antipsicotico insoluble en agua y esteres de sorbitan.
EP2827868B8 (en) * 2012-03-19 2019-12-18 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
WO2014080285A2 (en) * 2012-09-19 2014-05-30 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
JP6591546B2 (ja) * 2014-08-25 2019-10-16 アルカームス ファーマ アイルランド リミテッド 統合失調症治療用の持続放出型製剤におけるアリピプラゾール誘導体の結晶化プロセス

Also Published As

Publication number Publication date
PT3185867T (pt) 2021-04-12
US20190015408A1 (en) 2019-01-17
US11883394B2 (en) 2024-01-30
NZ729479A (en) 2021-03-26
AU2015306910A1 (en) 2017-03-16
US20210205302A1 (en) 2021-07-08
US10973816B2 (en) 2021-04-13
US10064859B2 (en) 2018-09-04
EP3185867B1 (en) 2021-01-13
US10478434B2 (en) 2019-11-19
RS61709B1 (sr) 2021-05-31
JP2017526747A (ja) 2017-09-14
MA40480B1 (fr) 2021-08-31
CA2959329C (en) 2023-06-27
EP3185867A1 (en) 2017-07-05
CN107106556A (zh) 2017-08-29
AU2015306910A8 (en) 2020-11-19
SI3185867T1 (sl) 2021-08-31
CA2959329A1 (en) 2016-03-03
DK3185867T3 (da) 2021-03-15
CY1124058T1 (el) 2022-05-27
LT3185867T (lt) 2021-06-10
ES2994850T3 (en) 2025-02-03
PL3185867T3 (pl) 2021-11-22
WO2016032950A1 (en) 2016-03-03
EP3185867A4 (en) 2018-01-24
US20240245676A1 (en) 2024-07-25
IL250661B (en) 2020-04-30
CN111454207B (zh) 2024-10-18
HUE054641T2 (hu) 2021-09-28
AU2015306910B2 (en) 2020-11-19
MA55917A (fr) 2022-03-16
EP3865476A1 (en) 2021-08-18
US20200108063A1 (en) 2020-04-09
EP3865476B1 (en) 2024-08-14
CN107106556B (zh) 2020-06-05
ES2862098T3 (es) 2021-10-07
AU2020264303A1 (en) 2020-11-26
SMT202100212T1 (it) 2021-07-12
AU2020264303B2 (en) 2022-10-13
US20160051546A1 (en) 2016-02-25
JP2019210296A (ja) 2019-12-12
CN111454207A (zh) 2020-07-28
IL250661A0 (en) 2017-04-30
JP6591546B2 (ja) 2019-10-16

Similar Documents

Publication Publication Date Title
HRP20210551T1 (hr) Postupak kristalizacije derivata aripiprazola u formulacijama sa produženim oslobađanjem za liječenje shizofrenije
HRP20210675T1 (hr) Mono- ili di-supstituirani derivati indola kao inhibitori replikacije denga virusa
HRP20211666T1 (hr) Oblici soli lumateperon ditozilata u krutom stanju
HRP20200538T1 (hr) Derivati pirimidina za liječenje virusnih infekcija
HRP20160886T1 (hr) Besilatna i tosilatna sol derivata dihidrokinazolina i njihova upotreba kao protuvirusna sredstva
JP2017526747A5 (enExample)
MX378717B (es) Acidos carboxilicos heterociclicos como activadores de guanilato ciclasa soluble.
MX389304B (es) Producto farmaceutico.
HRP20160813T1 (hr) Natrijeve i kalcijeve soli derivata dihidrokinazolina i njihova upotreba kao antivirusna sredstva
HRP20210183T1 (hr) 18f-obilježeni inhibitori specifičnog membranskog antigena prostate (psma) i njihova uporaba kao sredstava za vizualizaciju raka prostate
HRP20201644T1 (hr) Kristalni oblik 2-butoksi-7-(4-(pirolidin-1-ilmetil)benzil)-5h-pirolo [3,2-d]pirimidin-4-amina kao agonist tlr7, postupak njegove proizvodnje i njegova uporaba
HRP20211282T1 (hr) Oksisteroli i postupci njihovog korištenja
JP2017506666A5 (enExample)
WO2017177004A8 (en) Tertiary amides and method of use
HRP20221061T1 (hr) Postupak za pripremu sintetičkih intermedijera za pripremu tetrahidrokinolinskih derivata
FI3206692T3 (fi) Rasvamaksataudin hoito käyttäen glukokortikoidi- ja mineralokortikoidireseptorien antagonisteja
HRP20192286T1 (hr) Hidroksieitil sulfonat od ciklina ovisnog inhibitora kinaze proteina, njegov kristalni oblik, i postupak njegovog dobivanja
JP2019065019A (ja) ６−（（６，７−ジメトキシキナゾリン−４−イル）オキシ）−ｎ，２−ジメチルベンゾフラン−３−カルボキサミドの結晶形
WO2016166720A3 (en) Polymorphs of afatinib and its salts and process for the preparation of quinazolinyl derivatives
HRP20220234T1 (hr) Kristalni oblici
HRP20171707T1 (hr) Postupak proizvodnje rivaroksabana
RU2019106531A (ru) Кристалл соли производного хиназолина
MA35002B1 (fr) Forme cristalline delta du sel d'arginine du périndopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
HRP20191716T1 (hr) Čvrste oralne formulacije koje sadrže čvrste disperzije talina organskih kiselina u ksilitolu
RU2017131286A (ru) Новые полиморфные формы миноциклинового основания и способы их получения